news
The primary endpoint results of the Neuspera Phase II SANS UUI clinical study will be presented during the annual winter meeting of the Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU), February 26 – March 1, 2025, in Rancho Mirage, California. These pivotal trial results will support Neuspera’s FDA PMA submission for U.S. […]
Neuspera is looking forward to participating and presenting at the Piper Sandler 36th Annual Healthcare Conference early December. Steffen Hovard will provide an update on the progress and positive momentum for Neuspera in getting PMA approval for our micro-invasive system for treatment of overactive bladder. LinkedIn X
Our CEO and CMO, Steffen Hovard and Dr. Steven Siegel will be heading to Washington D.C. for this year’s American Urogynecologic Society PFD Week and are looking forward to connecting with old friends and meeting new ones. Reach out via LinkedIn or email to meet up. Hope to see you there! LinkedIn X
Did you know that this week is Urology Week 2024? To commemorate the occasion, MassDevice published an article on the top 10 urology device stories of 2024 so far and it featured our Series D round! LinkedIn X
The seasoned life sciences executive will play a key role as the company completes the regulatory process and prepares for commercialization of its Neuspera SNM System SAN JOSE, Calif., Sept. 12, 2024 /PRNewswire/ — Neuspera Medical, Inc., a neuromodulation company pioneering the Neuspera Sacral Neuromodulation (SNM) System, announced today that Bunty Banerjee has joined the company as its first Chief Operating […]
We’re excited to welcome two new members to our Neuspera team: Douglas Sullivan as Supply Chain Director and Jeff Siegel, CPA as Controller. We are grateful to have their expertise on the team as we continue working to improve sacral neuromodulation options for treating OAB!
Neuspera Medical is very excited and grateful for the tremendous interest in our progress towards reinventing sacral neuromodulation for treating OAB. The Neuspera Sacral Neuromodulation System includes innovations designed to significantly impact patient acceptance and satisfaction with this potentially life-changing therapy in a large market that has been largely underserved to date. Our two recent […]
Capital from Olympus Innovation Ventures, another strategic investor and several institutional investors will fund through expected PMA approval SAN JOSE, Calif., July 15, 2024 /PRNewswire/ — Neuspera Medical, Inc., a neuromodulation company pioneering the Neuspera Implantable Sacral Neuromodulation (SNM) System, announced the closing of its Series D funding round raising $23 million and led by Vertex Ventures HC and Treo […]
Check out this “stimulating” deep-dive conversation into how our respective technologies are shifting the paradigm for how patients with underlying neurological conditions may receive care in the not-too-distant future. LinkedIn X
65 Startups Named to MedTech Innovator 2024 Cohort